Evaluating Tasimelteon for Delayed Sleep-Wake Phase Disorder
Official title: A Double-Blind, Randomized, Two-Period Crossover Study to Evaluate the Effects of Tasimelteon Vs. Placebo in Subjects with Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant
Run by Vanda Pharmaceuticals · NCT06701396 · Data updated 2026-11-12
This study is testing if a new sleep medication called tasimelteon can help people with Delayed Sleep-Wake Phase Disorder who have a specific genetic variant improve their sleep patterns.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Vanda Pharmaceuticals Industry-sponsored |
| Locations | 1 site (Çankaya, Ankara) |
| Status | Recruiting |
| Started | October 8, 2024 |
| Main results expected | June 30, 2025 |
| Study ends | June 30, 2025 |
| Registry record updated | November 22, 2024 |
| Trial ID | NCT06701396 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are men and women aged 18 to 75 with a confirmed diagnosis of DSWPD and who are carriers of the CRY1Δ11 variant.
✕Probably not a fit
Patients who have had major surgery, trauma, or illness in the past 30 days, or who are pregnant or breastfeeding, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial is a double-blind, randomized, two-period crossover study designed to assess the efficacy and safety of a single oral dose of tasimelteon compared to a placebo in individuals diagnosed with Delayed Sleep-Wake Phase Disorder (DSWPD) who also carry the CRY1Δ11 genetic variant. Participants will be monitored for improvements in their sleep patterns and overall circadian rhythm. The study aims to gather data on how tasimelteon affects sleep-wake cycles in this specific patient population.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients suffering from DSWPD, potentially improving their quality of life.
How similar studies have gone: Other studies have explored treatments for sleep disorders, but the specific approach of using tasimelteon in this genetic context is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability and acceptance to provide written informed consent. * A confirmed clinical diagnosis of Delayed Sleep-Wake Phase Disorder (DSWPD). * Carrier of CRY1Δ11 variant. * Men or women between 18 - 75 years, inclusive. * Body Mass Index (BMI) of ≥ 18 and ≤ 40 kg/m\^2. Exclusion Criteria: * Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more days within the last 30 days. * Pregnancy, recent pregnancy (within 6 weeks), or women who are breastfeeding. * A positive test for substances of abuse. * Current tobacco user.
Where it's running
-
Vanda Investigational Site
Çankaya, Ankara, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Vanda Pharmaceuticals Inc.
- Email: VEC162@vandapharma.com
- Phone: 202-734-3400
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Remote ischemic conditioning for post-stroke insomnia
A 136-person, randomized study will test whether a non-invasive arm-cuff procedure done twice daily for 90 days can improve sleep after a first ischemic stroke in adults 18–80.
-
Chaihushugan Decoction vs Wen Dan Tang for Chronic Insomnia
This trial tests two traditional Chinese medicine formulas to see if one helps adults with chronic insomnia more than the other over 8 weeks.
-
Digital acupoint therapy plus education and exercise for sarcopenia and sleep in adults
This trial tests whether a remote program combining traditional Chinese medicine acupoint stimulation, health education, and exercise improves sarcopenia and sleep problems in adults and older adults.
-
Structured Combined Exercise Program for Postmenopausal Women
This trial tests whether a guided 12-week exercise program can improve heart health, menopausal symptoms, sleep, and quality of life in women aged 45–65 who are postmenopausal.
-
L. reuteri LM1063 for improving sleep
This trial will try a daily L. reuteri LM1063 probiotic to see if it helps adults (19–65) with poor sleep get better sleep.
-
Mind After Midnight — how being awake between 2:00 and 4:00 AM affects mood and decision-making
This project will test whether being awake during the biological night (2:00–4:00 AM) increases negative mood, poor decision-making, and suicidal thoughts in adults who have had suicidal ideation in the past six months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.